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ABSTRACT 
Background: The phase 3 MRC COIN trial showed no statistically significant benefit 
from adding the EGFR-target cetuximab to oxaliplatin-based chemotherapy in first-line 
treatment of advanced colorectal cancer. This study exploits additional information on HER2-
HER3 dimerization to achieve patient stratification and reveal previously hidden subgroups 
of patients who had differing disease progression and treatment response. 
Methods: HER2-HER3 dimerization was quantified by “FLIM Histology” in primary 
tumor samples from 550 COIN trial patients receiving oxaliplatin and fluoropyrimidine 
chemotherapy +/-cetuximab. Bayesian latent class analysis (LCA) and covariate reduction 
was performed to analyze the effects of HER2-HER3 dimer, RAS mutation and cetuximab 
on progression-free survival (PFS) and overall survival (OS). All statistical tests were two-
sided. 
Results: LCA on a cohort of 398 patients revealed two patient subclasses with 
differing prognoses (median OS: 1624 days [95%CI=1466-1816] vs 461 [95%CI=431-504]): 
Class 1 (15.6%) showed a benefit from cetuximab in OS (HR=0.43 [95%CI=0.25-0.76]; 
p=0.004). Class 2 showed an association of increased HER2-HER3 with better OS 
(HR=0.64 [95%CI=0.44-0.94]; p=0.02). A class prediction signature was formed and tested 
on an independent validation cohort (N=152) validating the prognostic utility of the dimer 
assay. Similar subclasses were also discovered in full trial dataset (N=1,630) based on 10 
baseline clinicopathological and genetic covariates.  
Conclusions: Our work suggests that the combined use of HER dimer imaging and 
conventional mutation analyses will be able to identify a small subclass of patients (>10%) 
who will have better prognosis following chemotherapy. A larger prospective cohort will be 
required to confirm its utility in predicting the outcome of anti-EGFR treatment.  
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The selection of patients who are likely to benefit from treatment with an EGFR 
inhibitor with first line chemotherapy for metastatic colorectal cancer (mCRC) remains 
controversial. Two major trials have compared the addition of cetuximab or bevacizumab for 
patients with KRAS wildtype colorectal cancer [1-3]. FIRE-3 showed a statistically significant 
survival benefit from cetuximab, in contrary to the US-based CALGB 0405 study, leading to 
intense debate [4]. Results show markedly improved overall survival (OS) compared to older 
trials, partially driven by the selection of the better prognosis KRAS wildtype population. The 
presence of any extended RAS mutation [5] was demonstrated to exclude patients from 
benefit of panitumumab in the PRIME trial; this is now enshrined in license [6].  
Other molecular factors also influence responsiveness to the addition of an EGFR 
inhibitor: the presence of a BRAF mutation and low expression of key EGFR ligands, 
epiregulin (EREG) or amphiregulin (AREG), both predict a lack of benefit [7, 8]. The primary 
tumor’s site of origin is also important. Tumors arising from the right, midgut derived, colon, 
falling in the arterial supply of the superior mesenteric artery, are more frequently methylated 
(with resulting low expression of EGFR ligands) [9-11], more often have mismatch repair 
deficiency, and carry a RAF mutation [12-14].  Left-sided cancers more often exhibit those 
features of responsiveness to EGFR treatment, namely high ligand expression and RAS and 
RAF wildtype. Initial reports also indicated that PIK3CA mutations may be associated with 
diminished responsiveness but these conclusions were from small studies (2-11 patients 
with PIK3CA mutations) [15, 16]. Larger studies did not show a statistically significant 
difference [17, 18], with the exception of one study showing that PIK3CA exon 20 mutation 
confers a poorer outcome [19]. Despite all this, reliable methods for the identification of 
patients who may benefit from EGFR antibody therapy remain elusive.  
In this paper we describe a novel approach to this problem. It is known that HER 
(ErbB) mediated signaling is initiated following dimerization between the same 
(homodimerization) or different HER family members (EGFR, ErbB/HER1-4) [20]. Dimers 
containing HER3, especially the HER2-HER3 heterodimer, have been shown to provide the 
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most potent proliferative signal to cancer cells [21].  Recently, we showed in preclinical 
experiments the HER2-HER3 can be modulated upon cetuximab treatment of colorectal 
cancer cells [22]. The same heterodimer has been demonstrated using archived primary 
breast cancer samples and contains statistically significant prognostic information which is 
independent of that of HER2 receptor expression status [23]. It is usually difficult to 
determine whether the receptors are forming dimers but the technique of Förster Resonance 
Energy Transfer (FRET) reports on the immediate proximity, only achieved during 
dimerization. The combination of FRET with time-domain Fluorescence Lifetime Imaging 
Microscopy (FLIM) allows the minute fluorescence signals to be detected [24]. Hence FRET-
FLIM represents the most exquisitely sensitive method for determining what proportion of a 
receptor is dimerized. 
Here we report the use of “FLIM Histology”, a technique using FRET-FLIM as a 
measure of the proportion of receptors in the HER2-HER3 dimer state, a concentration 
independent parameter, based on a well-established gold standard technique to probe 
endogenous protein-protein interactions in cells [23, 25-30]. In 550 patients from the MRC 
COIN trial [31], combining the use of HER dimer measurement and recently reported 
Bayesian statistical methods [32-34], we aimed to identify subclasses of patients with 
different prognostic outcomes.  
MATERIALS AND METHODS 
Patients and Treatment 
In the MRC COIN trial (ISRCTN79877428) [31] patients with histologically confirmed 
adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable 
disease (RECIST v1.0), and were fit for first line combination chemotherapy, were 
randomized in a 1:1:1 ratio to receive the control arm of continuous oxaliplatin-based 
chemotherapy (A), or continuous chemotherapy plus cetuximab (B), or intermittent 
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chemotherapy (C).  This study was restricted to arms A and B. Two chemotherapy regimens, 
XELOX or OxMdG (oxaliplatin with modified deGramont, a FOLFOX variant), were used.   
Objectives and Outcome Measures 
The primary objective of the COIN A vs B comparison was to determine whether the 
addition of cetuximab to continuous chemotherapy resulted in improved outcome in patients 
with KRAS wildtype (WT) tumors. Overall Survival (OS) was calculated as time from 
randomization to death from any cause. Survivors were censored at the last known alive 
date. Progression Free Survival (PFS) was calculated as the interval from randomization to 
first evidence of progression or death from any cause.  Survivors without progression were 
censored at the last known alive date. 
Patient Samples and Imaging 
This study was approved by the Trial Steering Committee and FRET-FLIM was limited 
to those patients who had given written informed consent for ‘other bowel cancer research’, 
in whom sufficient residual pathological specimen was available.  
Patient tissue micro-arrays (TMAs) were retrieved from the Wales Cancer Bank and 
processed at King’s College London. Two consecutive slices of all TMAs underwent antigen 
retrieval in a Ventana BenchMark system and were stained with anti-HER3-IgG-Alexa546 
(‘donor’ or ‘D’ slice) and in addition with anti-HER2-IgG-Cy5 (‘donor with acceptor’ or ‘DA’ 
slice) and mounted as described previously [26]. 
TMA slices were imaged on an “open” automated FLIM microscope [35]. FLIM 
analysis was performed with the TRI2 software (v2.7.8.9, CRUK/MRC Oxford Institute for 
Radiation Oncology, Oxford) [36-38]. Autofluorescence effects were minimized with a 
lifetime filtering algorithm [39]. The FRET efficiency for each tissue region was calculated 
according to FRET efficiency = 1–(DA/D), where D and DA are the average lifetime of 
Alexa546 in the matching D and DA images respectively. FRET efficiency (denoted: 
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“FRET”), and FRET efficiency multiplied by HER3 fluorescence intensity, representing the 
amount of dimerized HER3, (“FRET x HER3”) were calculated as continuous variables 
(Supplementary Figure 1).  
The use of formol saline fixation, as opposed to neutral buffered formalin, resulted in 
excessive amounts of contaminating autofluorescence. These samples (292 patients) were 
excluded. 
TMAs from the 398-patient training set and the 152-patient validation set were 
received and processed independently in two batches. All analysis of the training set was 
performed before the validation TMAs were received, and was therefore performed 
completely blind and without knowledge of the validation set. 
Statistical Analysis 
Bayesian latent class analysis (LCA) was performed using the model described by 
Rowley et al. [32] (ALPACA v0.2.15), which seeks to detect and map association and base 
hazard rate heterogeneity. This results in objective cohort stratification, driven strictly by 
observed and statistically significant regularities in the data. Specification of the number of 
latent classes and the complexities of class-dependent base hazard rates, is based on 
Bayesian model selection. Patients were retrospectively assigned to latent groups according 
to maximum a posteriori class membership probability.  
Covariate reduction and the generation of predictive signatures was performed by 
Bayesian multivariate survival analysis with repeated cross-validation and backwards 
elimination with the aim of reducing overfitting [33]. 
Kaplan-Meier plots and log-rank statistics were produced using the R ‘survival’ 
package (v2.42-3, R v3.5.1). When p<0.05 the result was considered statistically significant 
and all tests were two-sided. 
RESULTS 
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Tissues from two cohorts of 398 and 152 patients (the ‘FRET’ training and validation 
cohorts respectively) were analyzed for HER2-HER3 dimerization. All patients also formed a 
‘full’ cohort of 1,630 patients. Figure 1 summarizes the patient selection for imaging and 
analysis and Table 1 contains the cohort patient characteristics. A continuous distribution of 
FRET efficiency with a mean value of 1.6%, (lower quartile 0.18%, upper quartile 2.7%) was 
recorded. Figure 2 shows typical images and FRET efficiency maps. 
LCA was performed on the FRET training cohort for both outcomes using, a minimal, 4 
covariates: FRET; FRET x HER3 (since HER protein concentration information is 
independent of dimer [40]); Treatment Arm (to give the algorithm the ability to detect groups 
with different responses); and RAS mutation status (because of its known association with 
cetuximab treatment).  
We report evidence of two novel latent classes in the 398-patient training set, with both 
PFS and OS analysis. The hazard ratios (HR) assigned to each covariate for each class is 
shown in Figure 3A-B. Based on PFS, 44/398 (11.1%) of patients were retrospectively 
assigned to Class 1, the remainder to Class 2; for OS 62/398 (15.6%) were assigned to 
Class 1. Figure 3C-D shows Kaplan-Meier plots split by class and treatment (TRT). Class 1 
patients had a better prognosis (median OS: 1624 days [95%CI=1466-1816] vs 461 
[95%CI=431-504]) and a predictive response to cetuximab which was more pronounced in 
OS: Class 1 TRT HR=0.43 [95%CI=0.25-0.76] logrank p=0.003 (median OS: 1447 days vs 
1668 days; difference = 221 days, see Supplementary Methods for more details). This is 
statistically significantly larger than among all patients in the cohort (median OS: 505 days vs 
581 days; difference = 76 days).  
The second and consistently larger group (Class 2) did not show a statistically 
significant benefit from cetuximab (PFS: HR=0.93 [95%CI=0.69-1.25], p=0.62, OS: HR=1.03 
[95%CI=0.74-1.42], p=0.88), however, increased FRET efficiency was associated with 
improved outcome (PFS: HR=0.63 [95%CI=0.46-0.88], p=0.006, OS: HR=0.64 
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[95%CI=0.44-0.94], p=0.02) (Figure 3A,C). Figure 3E-F shows Kaplan-Meier curves split by 
class and FRET demonstrating the benefit of cetuximab to those with a high FRET score. 
FRET x HER3 did not have a statistically significant HR.  
Table 2 shows the characteristics of the patient classes and gives an indication of 
which parameters may be useful in a prospective patient classifier (p<0.05): FRET 
(Supplementary Figure 2), liver-only metastases, PIK3CA mutation status, RECIST sum of 
longest diameter, neutrophil count, white blood cell count, pain at baseline, haemoglobin  
and alkaline phosphatase. 
Additional LCA was performed without the FRET parameters and determined that 
there was insufficient evidence for distinct latent groups. The HER2-HER3 FRET efficiency 
data therefore conveys significant additional information. 
As validation of this class structure we sought further evidence in the full COIN cohort 
(1,630 patients, including FRET cohorts) for whom clinical and genomic data was available. 
To maximize the utility of any findings for patient stratification we performed analysis with all 
available baseline covariates (115 covariates including missingness indicators, expanded 
categorical data and TRT, see Supplementary Methods). These were subject to Bayesian 
covariate reduction against OS and we identified a signature that combined 10 covariates 
(WHO performance status, previous adjuvant chemotherapy status, RECIST sum of longest 
diameter, number of metastatic sites, EREG, RAS status (KRAS or NRAS), BRAF status, 
neutrophil count, alkaline phosphatase and pain).  
These 10 covariates, plus TRT, in the full cohort were subject to OS-based LCA which 
revealed that three classes were most likely (Figure 4A). Class 1 (N=93/1630) indicates a 
possibility of a positive response to cetuximab (HR=0.71 [95%CI=0.45-1.14], p=0.16), Class 
2 (N=350/1630) shows no response (HR=0.94 [95%CI=0.70-1.25], p=0.66) and Class 3 
(N=1187/1630) shows a statistically significant negative response (HR=1.34 [95%CI=1.10-
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1.71], p=0.005). This is reflected in the Kaplan-Meier curve split by class and TRT (Figure 
4B). PFS-based LCA did not reveal interesting classes. 
To investigate the overlap in membership of individual patients between the classes of 
the two LCA analyses from the FRET cohort and the full cohort, the class membership table 
for the 398 FRET cohort patients is presented in Figure 4C. A permutations test (100,000 
random permutations of 398 patients into classes in these proportions) indicated a 
probability of <1/100,000 for obtaining this overlap in membership by chance. LCA was also 
performed on the non-overlapping set of 1,232 patients (1,630 minus 398) and a similar 
three groups were found (See Supplementary Figure 3).  
In the FRET cohort there was a statistically significant association of PIK3CA mutation 
with better OS (median 875 vs 504 days, logrank p=0.03, Supplementary Figure 4), which 
agrees with the observation of a higher proportion of PIK3CA mutant in the responding Class 
1. This association was not detectable in the full cohort. A breakdown into exon 9 or exon 20 
PIK3CA mutation groups did not reveal any statistically significant differences in PFS or OS, 
in either cohort (FRET cohort: exon 9, N=37/398, exon 20, N=12/398; full cohort exon 9, 
N=106/1630, exon 20, N=50/1630). 
To form a covariate signature that may predict class membership we performed 
Bayesian covariate reduction on the union of the nine covariates identified in Table 2 and 
the 10 prognostic baseline covariates: total 15. The resulting signature contained seven 
statistically significant covariates (RECIST sum of longest diameter, neutrophil count, white 
blood cell count, haemoglobin, PIK3CA mutation status, liver-only metastases and FRET) 
with associated weights (Figure 5A). 
The performance against the LCA class assignment of the 398 is shown in Figure 5B 
(AUC: 0.753). The signature was used as a classifier, by selecting an optimal point on the 
ROC curve (according to Youden’s index) with specificity of 0.677 and sensitivity of 0.708. 
The results on the 398 training set and the independent validation set of 152 are shown in 
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Figure 5C-D with survival curves split by class and treatment. The re-classification of the 
398 patients using the new signature-based classifier clearly retains the prognostic 
(p=0.001, chemo only patients) and predictive (p=0.04) elements of the classes. In the 152-
patient validation set we again recreate the prognostic behavior (p=0.04 (both TRT arms), 
p=0.09 (chemo only patients)).  
Another signature was produced without FRET (from 14 parameters, Figure 5E) and 
Figure 5F-G demonstrate that the with-FRET signature has prognostic power in the 
validation set, where the without-FRET signature does not. The interplay of FRET with the 
other covariates is explored in Supplementary Figure S5. 
DISCUSSION 
The selection of patients for EGFR-inhibitor treatment for mCRC remains difficult. With 
KRAS WT patients, the addition of EGFR-targeted treatment (cetuximab/panitumumab) to 
irinotecan or oxaliplatin chemotherapy [1, 6, 41, 42], is associated with a statistically 
significant survival benefit in three of four phase 2/3 trials [1, 6, 42]. However, the 
improvement of median PFS was only around 1-2 months. In the phase 2 OPUS trial, 
addition of cetuximab to FOLFOX4 resulted in a statistically significant improvement in PFS 
(8.3 months vs 7.2 months, p=0.006) [42]. In contrast, the NORDIC VII trial reported no 
benefits from adding cetuximab to oxaliplatin-based regimen (with bolus 5-FU) [41].  EGFR 
immunohistochemistry is not a sufficient predictive factor for clinical benefit for cetuximab in 
the KRAS WT population [43, 44].  
 Further molecular stratification by identifying novel subgroups will make a meaningful 
contribution towards assessing the efficacy of EGFR targeting in future clinical trials. Here 
we present the application of our recently improved and validated [23] FLIM Histology 
analysis method for quantification of HER2-HER3 dimer in FFPE samples from the 
randomized phase 3 MRC COIN trial. Using FLIM-based molecular imaging parameters and 
a recently published Bayesian statistical method [32] we have shown that there are two 
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classes of patients with mCRCTable 2, Figure 3. Class 1 (10-15% of patients) had a better 
prognosis and also benefited from addition of cetuximab to the standard chemotherapy. 
Within Class 2 (85-90% of patients), patients have less favorable survival (median PFS circa 
7.5 months) and no benefit from cetuximab.   
To validate these results we formed a biomarker that predicts class membership by 
creating a novel signature of seven parameters that were pre-determined by the two 
Bayesian latent class analyses.  This was applied to the training set of 398 and we retained 
the predictive and prognostic elements of, the smaller, Class 1. Notably, the prognostic 
effect on survival (195 days, comparing chemotherapy only patients between Classes 1 and 
2) was larger than the predictive effect (136 days, comparing Class 1 patients with/without 
cetuximab). Application of the signature to the completely independent validation set of 152 
patients was sufficient to validate the prognostic (but not the predictive) utility. In addition, we 
found that patients exhibiting a high FRET value are more likely to be in the worst prognostic 
outcome subclass i.e. Class 2 (Table 2) as reflected in the class prediction signature (Figure 
5A). However, within Class 2 a high FRET value can be indicative of better outcome within 
that class dependent on the other signature covariates. Importantly, the class prediction 
(seven-parameter) signature is entirely dependent on the inclusion of the HER2-HER3 dimer 
quantity. 
We chose HER2-HER3 because it has been shown to be the most tumor promoting 
dimer among EGFR family members, due to its downstream activation of PI3-kinase 
(PI3K)/AKT and MAPK pathways [45-47]. Secondly, the mRNA expression of alternative 
ligands such as EREG, which has been shown to modulate the efficacy of EGFR-targeted 
agents in KRAS WT mCRCs [7], is the broadest specificity EGF-like ligand that induces the 
widespread phosphorylation of HER1-4 [48]. Although the mechanism of this modulation is 
not precisely known, EREG, as opposed to EGF, can recruit HER3 into heterodimers, as 
reflected by its enhancement on the proliferative activity on cells co-expressing a 
combination of HER3 with either HER2 or HER4 [49]. Thirdly, we showed by FRET-FLIM 
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imaging, an induction of HER2-HER3 dimers after cetuximab treatment in KRAS and BRAF 
WT colon cancer cells [22].  
The additional HER2-HER3 dimer parameter as measured by FLIM may be important 
for the future stratification of anti-HER2 treatment combination using pertuzumab plus 
trastuzumab [50]. Notably, HER2 activity (of prognostic signature) has been shown 
previously to be measurable by FLIM independently of HER2 concentration [23].  
This new retrospective analysis suggests that the proportion of patients gaining benefit 
from cetuximab may be as small as 10% and concurs with clinical data that these patients 
are amongst those with the best baseline prognosis. HER2-HER3 FRET-FLIM provided new 
information enabling the statistical method to identify this latent class.  This hypothesis 
generating data shows the potential of measurement of dimers and demonstrates the utility 
of FRET-FLIM to assess dimerization in FFPE tissue.  
Further preclinical experiments, using patient derived organoids for example, are 
needed to understand the statistically significantly increased prevalence of PIK3CA 
mutations in the discovered Class 1. Previously anti-EGFR response was shown to be 
higher for RAS WT patients who expressed pEGFR and pAkt [51]. pAkt may in turn be linked 
to EGFR trafficking and degradation, and therefore treatment response, warranting further 
study [52]. Furthermore, the predictive utility of this assay may be further enhanced by the 
inclusion of pre- and post-treatment dimer measurements as we have recently demonstrated 
in a Phase 2 head and neck study using an exosomal HER dimer assay [53]. 
In conclusion, this study demonstrates how a novel Bayesian LCA, signature 
generation and covariate reduction can be used as objective approaches to generate 
hypotheses for treatment. Given that the identification of prognostic and predictive 
biomarkers and clinical characteristics in colorectal cancers is an active area of research, 
this study shows how the development and application of statistical methods contributes to 
the retrospective analysis of trials. The ability to model and quantify the evidence for putative 
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patient stratifications is therefore a crucial initial step towards identifying and validating 
strategies for targeting therapies. 
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Table 1: Patient characteristics of the Full and FRET cohorts. 
Covariate Full Cohort FRET Training FRET Validation 
N 1630 398 152 
TRT = B (%)     815 (50.0)     209 (52.5)      80 (52.6)  
CHEMO = XELOX (%)    1070 (65.6)     223 (56.0)     111 (73.0)  
Age (at randomisation) (mean (sd))   62.34 (9.79)  63.04 (9.60)  62.77 (9.12) 
SEX = Male (%)    1069 (65.6)     278 (69.8)      95 (62.5)  
Height (cm) (mean (sd))  170.10 (9.33) 170.14 (9.13) 169.65 (8.92) 
Weight (Kg) (mean (sd))   76.05 (15.98)  75.66 (15.63)  78.02 (17.39) 
WHO performance status (mean (sd))    0.62 (0.62)   0.58 (0.59)   0.62 (0.65) 
Sidedness of primary tumour (%)             
   Left-sided    1138 (69.8)     274 (68.8)     103 (67.8)  
   Right-sided     460 (28.2)     117 (29.4)      48 (31.6)  
   unknown      32 ( 2.0)       7 ( 1.8)       1 ( 0.7)  
TSTAT (%)             
   Local recurrence      88 ( 5.4)      24 ( 6.0)      18 (11.8)  
   Resected     865 (53.1)     315 (79.1)     115 (75.7)  
   Unresected/unresectable     677 (41.5)      59 (14.8)      19 (12.5)  
Number of metastatic sites = polymetastatic (>3) (%)      71 ( 4.4)      17 ( 4.3)       6 ( 3.9)  
mlivonly = Yes (%)     368 (22.6)      98 (24.6)      34 (22.4)  
metscat (%)             
   Metachronous     489 (30.0)     159 (39.9)      68 (44.7)  
   Synchronous    1123 (68.9)     237 (59.5)      84 (55.3)  
   unknown      18 ( 1.1)       2 ( 0.5)       0 ( 0.0)  
MNODE = Yes (%)     720 (44.2)     172 (43.2)      75 (49.3)  
Tumour marker: CEA value (mean (sd))  686.99 (2849.05) 374.37 (1310.56) 484.72 (1463.96) 
Tumour marker: CA 19-9 value (mean (sd)) 2946.00 (13052.42) 546.26 (705.36) 254.50 (152.78) 
EREG Cq value, negated (mean (sd))   -3.16 (2.26)  -3.28 (2.27)  -3.10 (2.01) 
AREG Cq value, negated (mean (sd))   -2.82 (1.60)  -2.84 (1.58)  -2.73 (1.65) 
KRAS (%)             
   Mutation     570 (35.0)     165 (41.5)      73 (48.0)  
   Wild-type     744 (45.6)     225 (56.5)      78 (51.3)  
   unknown     316 (19.4)       8 ( 2.0)       1 ( 0.7)  
NRAS (%)             
   Mutation      51 ( 3.1)      17 ( 4.3)       5 ( 3.3)  
   Wild-type    1259 (77.2)     374 (94.0)     147 (96.7)  
   unknown     320 (19.6)       7 ( 1.8)       0 ( 0.0)  
MSI (%)             
   MSI      45 ( 2.8)      15 ( 3.8)       5 ( 3.3)  
   Stable     977 (59.9)     314 (78.9)     132 (86.8)  
   unknown     608 (37.3)      69 (17.3)      15 ( 9.9)  
PIK3CA (%)             
   Mutation     156 ( 9.6)      49 (12.3)      26 (17.1)  
   Wild-type    1107 (67.9)     334 (83.9)     126 (82.9)  
   unknown     367 (22.5)      15 ( 3.8)       0 ( 0.0)  
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BRAF (%)             
   Mutation     102 ( 6.3)      29 ( 7.3)      11 ( 7.2)  
   Wild-type    1192 (73.1)     360 (90.5)     141 (92.8)  
   unknown     336 (20.6)       9 ( 2.3)       0 ( 0.0)  
ADJCH (%)             
   >1m and <6m ago      68 ( 4.2)      24 ( 6.0)       8 ( 5.3)  
   >6 months ago     261 (16.0)      82 (20.6)      33 (21.7)  
   No    1218 (74.7)     269 (67.6)      99 (65.1)  
   Yes (unspecified)      83 ( 5.1)      23 ( 5.8)      12 ( 7.9)  
Sum of longest diameter (mean (sd))  106.65 (85.19) 103.88 (81.57)  96.05 (70.83) 
Platelet count (mean (sd))  356.31 (132.62) 346.38 (119.65) 329.67 (132.96) 
Neutrophil count (mean (sd))    6.29 (3.58)   5.77 (2.64)   5.96 (4.94) 
White blood cell count (mean (sd))    8.98 (3.99)   8.51 (3.06)   8.26 (2.92) 
Alkaline phosphatase (mean (sd))  191.67 (176.79) 180.77 (171.20) 170.72 (145.04) 
PAIN at baseline (CTC grade) (mean (sd))    0.55 (0.74)   0.49 (0.72)   0.38 (0.66) 
Anorexia at baseline (CTC grade) (mean (sd))    0.23 (0.54)   0.20 (0.50)   0.12 (0.37) 
Vomiting at baseline (CTC grade) (mean (sd))    0.04 (0.24)   0.03 (0.21)   0.02 (0.14) 
Lethargy at baseline (CTC grade) (mean (sd))    0.49 (0.65)   0.44 (0.60)   0.38 (0.61) 
Haemaglobin at baseline (CTC grade) (mean (sd))    0.25 (0.56)   0.20 (0.47)   0.12 (0.40) 
Nail changes at baseline (CTC grade) (mean (sd))    0.01 (0.09)   0.02 (0.14)   0.00 (0.00) 
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Table 2: Patient characteristics of the 2 discovered latent classes for PFS and OS from the 
FRET cohort. 
Covariate PFS Class 1 PFS Class 2 
p-
value* OS Class 1 OS Class 2 
p-
value* 
n 44 354  62 336  
Treatment arm = B (%)     31 (70.5)     178 (50.3)  0.02     40 (64.5)     169 (50.3)  0.05 
CHEMO = XELOX (%)     20 (45.5)     203 (57.3)  0.18     33 (53.2)     190 (56.5)  0.73 
Age (at randomisation) 
(mean (sd))  61.64 (10.65)  63.22 (9.47) 0.30  61.65 (11.71)  63.30 (9.16) 0.21 
Sex = Male (%)     29 (65.9)     249 (70.3)  0.67     41 (66.1)     237 (70.5)  0.59 
Height (cm) (mean (sd)) 170.16 (8.78) 170.13 (9.19) 0.99 169.87 (8.95) 170.19 (9.18) 0.80 
Weight (Kg) (mean (sd))  74.40 (12.93) 
 75.82 
(15.94) 0.57  74.92 (14.11)  75.80 (15.91) 0.68 
WHO performance 
status (mean (sd))   0.43 (0.59)   0.60 (0.59) 0.07   0.45 (0.56)   0.61 (0.59) 0.06 
Sidedness of primary 
tumour (%)          0.22          0.93 
   Left-sided     35 (79.5)     239 (67.5)       44 (71.0)     230 (68.5)   
   Right-sided      9 (20.5)     108 (30.5)       17 (27.4)     100 (29.8)   
   unknown      0 ( 0.0)       7 ( 2.0)        1 ( 1.6)       6 ( 1.8)   
Baseline tumour status 
(%)          0.006          0.01 
   Local recurrence      7 (15.9)      17 ( 4.8)        6 ( 9.7)      18 ( 5.4)   
   Resected     34 (77.3)     281 (79.4)       54 (87.1)     261 (77.7)   
   
Unresected/unresectable      3 ( 6.8)      56 (15.8)        2 ( 3.2)      57 (17.0)   
Number of metastatic 
sites = polymetastatic 
(>3) (%)      0 ( 0.0)      17 ( 4.8)  0.28      1 ( 1.6)      16 ( 4.8)  0.43 
Liver-only metastases = 
Yes (%)     17 (38.6)      81 (22.9)  0.04     24 (38.7)      74 (22.0)  0.008 
Timing of metastases (%)          0.88          0.70 
   Metachronous     18 (40.9)     141 (39.8)       27 (43.5)     132 (39.3)   
   Synchronous     26 (59.1)     211 (59.6)       35 (56.5)     202 (60.1)   
   unknown      0 ( 0.0)       2 ( 0.6)        0 ( 0.0)       2 ( 0.6)   
Nodal metastases status 
= Yes (%)     18 (40.9)     154 (43.5)  0.87     24 (38.7)     148 (44.0)  0.52 
Tumour marker: CEA 
value (mean (sd)) 274.76 (641.77) 
384.72 
(1361.65) 0.67 594.24 (2987.25) 339.65 (774.76) 0.24 
Tumour marker: CA 19-9 
value (mean (sd)) 278.00 (382.52) 
586.50 
(740.01) 0.49 719.00 538.41 (720.93)   
EREG Cq value, negated 
(mean (sd))  -2.90 (2.09)  -3.32 (2.29) 0.31  -2.97 (2.55)  -3.33 (2.23) 0.32 
AREG Cq value, negated 
(mean (sd))  -2.65 (1.59)  -2.86 (1.58) 0.46  -2.69 (1.53)  -2.86 (1.59) 0.48 
KRAS mutation status (%)          0.39          0.54 
   Mutation     14 (31.8)     151 (42.7)       22 (35.5)     143 (42.6)   
   Wild-type     29 (65.9)     196 (55.4)       39 (62.9)     186 (55.4)   
   unknown      1 ( 2.3)       7 ( 2.0)        1 ( 1.6)       7 ( 2.1)   
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NRAS mutation status 
(%)          0.50          0.46 
   Mutation      1 ( 2.3)      16 ( 4.5)        2 ( 3.2)      15 ( 4.5)   
   Wild-type     43 (97.7)     331 (93.5)       60 (96.8)     314 (93.5)   
   unknown      0 ( 0.0)       7 ( 2.0)        0 ( 0.0)       7 ( 2.1)   
Microsatellite stability 
status (%)          0.53          0.78 
   MSI      2 ( 4.5)      13 ( 3.7)        2 ( 3.2)      13 ( 3.9)   
   Stable     37 (84.1)     277 (78.2)       51 (82.3)     263 (78.3)   
   unknown      5 (11.4)      64 (18.1)        9 (14.5)      60 (17.9)   
PIK3CA mutation status 
(%)          0.37          0.009 
   Mutation      6 (13.6)      43 (12.1)       14 (22.6)      35 (10.4)   
   Wild-type     38 (86.4)     296 (83.6)       48 (77.4)     286 (85.1)   
   unknown      0 ( 0.0)      15 ( 4.2)        0 ( 0.0)      15 ( 4.5)   
BRAF mutation status (%)          0.54          0.89 
   Mutation      5 (11.4)      24 ( 6.8)        4 ( 6.5)      25 ( 7.4)   
   Wild-type     38 (86.4)     322 (91.0)       57 (91.9)     303 (90.2)   
   unknown      1 ( 2.3)       8 ( 2.3)        1 ( 1.6)       8 ( 2.4)   
Adjuvant chemotherapy 
(%)          0.71          0.83 
   >1m and <6m ago      3 ( 6.8)      21 ( 5.9)        4 ( 6.5)      20 ( 6.0)   
   >6 months ago     10 (22.7)      72 (20.3)       13 (21.0)      69 (20.5)   
   No     27 (61.4)     242 (68.4)       43 (69.4)     226 (67.3)   
   Yes (unspecified)      4 ( 9.1)      19 ( 5.4)        2 ( 3.2)      21 ( 6.2)   
Sum of longest diameter 
(mean (sd))  81.66 (74.30) 
106.67 
(82.11) 0.05  68.39 (52.90) 110.49 (84.28) <0.001 
Platelet count (mean 
(sd)) 348.34 (109.90) 
346.13 
(120.95) 0.91 341.32 (99.13) 347.31 (123.18) 0.72 
Neutrophil count (mean 
(sd))   4.76 (1.69)   5.90 (2.71) 0.007   5.10 (1.73)   5.90 (2.76) 0.03 
White blood cell count 
(mean (sd))   7.50 (2.15)   8.63 (3.14) 0.02   7.98 (2.28)   8.61 (3.18) 0.14 
Alkaline phosphatase 
(mean (sd)) 171.11 (207.48) 
181.98 
(166.44) 0.69 140.52 (150.16) 188.22 (174.00) 0.04 
PAIN at baseline (CTC 
grade) (mean (sd))   0.32 (0.60)   0.51 (0.74) 0.09   0.32 (0.65)   0.52 (0.73) 0.05 
Anorexia at baseline (CTC 
grade) (mean (sd))   0.09 (0.29)   0.21 (0.51) 0.13   0.16 (0.45)   0.20 (0.50) 0.53 
Vomiting at baseline 
(CTC grade) (mean (sd))   0.00 (0.00)   0.03 (0.22) 0.31   0.00 (0.00)   0.04 (0.23) 0.22 
Lethargy at baseline (CTC 
grade) (mean (sd))   0.34 (0.57)   0.45 (0.60) 0.24   0.32 (0.57)   0.46 (0.60) 0.09 
Haemaglobin at baseline 
(CTC grade) (mean (sd))   0.09 (0.29)   0.22 (0.49) 0.09   0.10 (0.30)   0.22 (0.50) 0.05 
Nail changes at baseline 
(CTC grade) (mean (sd))   0.00 (0.00)   0.02 (0.15) 0.31   0.00 (0.00)   0.02 (0.15) 0.22 
FRET: HER2-HER3 FRET 
efficiency (mean (sd))   0.01 (0.02)   0.02 (0.02) 0.006   0.01 (0.02)   0.02 (0.03) 0.10 
FRET x HER3 intensity 
(mean (sd))   0.26 (1.37)   0.66 (1.81) 0.15   0.52 (1.26)   0.64 (1.85) 0.63 
*Chi-squared test for categorical values or ANOVA for continuous variables, all two-sided. 
21 
 
FIGURES 
Figure 1 
 
Figure 1: CONSORT diagram of patient selection and analysis flow for the FRET 
cohorts that were subject to dimer imaging and the Full Cohort. Patients excluded at 
the TMA and Image quality control stage had insufficient tissue remaining on the slide or the 
tissue was of bad quality (e.g. folded) or the donor and donor-acceptor areas could not be 
matched. Class membership revealed by the Latent Class Analysis on the FRET cohort of 
398 was used to train a class membership signature, which was tested in the validation set 
of 152 patients. The concordance between the latent class analysis on the FRET and Full 
cohorts was assessed in a class overlap comparison. FS = formol saline. Treatment arms: 
A=Oxaliplatin and Fluoropyrimidine Chemotherapy, B=A+Cetuximab, C=Intermittent 
Chemotherapy. 
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Figure 2 
 
Figure 2: Detection of HER2-HER3 dimerization by FLIM. Pseudo colour FRET efficiency 
maps indicate degree of HER2-HER3 interaction. Scale bar = 50 m.  
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Figure 3 
 
Figure 3: Multivariate latent class analysis (LCA) of the FRET cohort. A,B) Tables of 
covariate associated hazard ratios for the 2 discovered classes. For those in Class 1, 
Treatment Arm B (cetuximab) was protective (for OS, squares). For those in Class 2, a high 
FRET HER2-HER3 dimer score was protective (circles). C,D) Survival curves split by class 
and treatment arm to show potential prognostic and predictive value, for OS and PFS. Log 
rank p-values for prognostic and predictive splits show that FRET-based LCA with 398 
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patients has a clear prognostic (log-rank p<0.001) and a potential predictive value: 
Cetuximab (TRT arm B) was effective for patients in OS Class 1 (log-rank p=0.05). E,F) 
Survival curves split by class and FRET efficiency. The statistically significant HR associated 
with FRET in Class 2 is demonstrated. Patients in Class 2 have a better outcome if their 
HER2-HER3 FRET Efficiency is in the upper tertile (PFS log-rank p<0.001, OS log-rank 
p=0.02). All statistical tests were two-sided. 
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Figure 4 
 
Figure 4: Latent Class Analysis testing for similar classes within the full cohort using 
baseline covariates and OS. A) Table of covariates of statistical significance. B) Kaplan-
Meier plot split by class and treatment arm. The 3 classes are prognostic (log-rank p<0.001). 
Class 3 predicts a treatment response (log-rank p<0.001). C) LCA OS Class membership 
comparison between the 398 FRET cohort (2 classes, Figure 3) and the overlap with the full 
cohort (3 classes). A randomised permutations test indicates a non-random overlap of 
patients with the class sets. All statistical tests were two-sided. 
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Figure 5 
 
Figure 5: Mixed covariate class prediction signatures with and without FRET. A) Table 
of selected covariates in the with-FRET signature, ranked by importance. The Weight 
indicates how each covariate should be combined to form a class prediction score, with a 
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constant that gives the signature a zero mean. Class 2 is associated with a signature score 
> -0.335. High FRET favours Class 2 because of its positive weight. B) ROC curve for the 
class prediction score showing it’s performance in predicting the class of the 398 patients in 
the training set (Specificity=0.677, Sensitivity=0.708) and the optimal class threshold (-
0.335). C,D) Survival curves split by class and treatment arm for the training set and 
independent validation set, respectively. E) Table of selected covariates in the without-FRET 
signature. F,G) Survival curves split by class for the with- and without-FRET signatures 
applied to the 152 validation set. FRET provides information that splits the classes (log rank 
p-value=0.04). 
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